ArticleEuropean journal of endocrinology2021
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Article in European journal of endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.Pituitary · 2026Review
- Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.Pituitary · 2026Article
- Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Local growth hormone promotes benign prostatic hyperplasia.JCI insight · 2026Article
- Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.Endocrinology · 2026Article
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Article
- Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.Pituitary · 2026Article
- Review
- Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.Pituitary · 2026Article
- Pegvisomant in managing comorbidities of acromegaly: a review.Reviews in endocrine & metabolic disorders · 2026Review
- Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.Frontiers in endocrinology · 2026Article
- Acromegaly treatment and bone: a bidirectional relationship.Pituitary · 2025Review
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Disease-Specific Mortality in Patients With Acromegaly Treated With Pegvisomant: An ACROSTUDY Analysis.Endocrine connections · 2025Article
- Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.Journal of comparative effectiveness research · 2025Article
- Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism.International journal of molecular sciences · 2025Review
- Preoperative medical therapy for acromegaly: current knowledge and clinical significance.Frontiers in endocrinology · 2025Review
- Personalized Medicine in Acromegaly: The ACROFAST Study.The Journal of clinical endocrinology and metabolism · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.
designGlobal (15 countries), multicentre, non-interventional study (2004-2017).
methodsThe complete ACROSTUDY cohort comprised patients with acromegaly, who were being treated with pegvisomant (PEGV) prior to the study or at enrolment. The main endpoints were long-term safety (comorbidities, adverse events (AEs), pituitary tumour volumes, liver tests) and efficacy (IGF1 changes).
resultsPatients (n = 2221) were treated with PEGV for a median of 9.3 years (range, 0-20.8 years) and followed up for a median of 7.4 years (range, 0-13.9 years). Before PEGV, 96.3% had received other acromegaly treatments (surgery/radiotherapy/medications). Before PEGV treatment, 87.2% of patients reported comorbidities. During ACROSTUDY, 5567 AEs were reported in 56.5% of patients and of these 613 were considered treatment-related (in 16.5% of patients) and led to drug withdrawal in 1.3%. Pituitary imaging showed a tumour size increase in 7.1% of patients; the majority (71.1%) reported no changes. Abnormal AST or ALT liver tests occurred in 3.2% of patients. IGF1 normalization rate improved over time, increasing from 11.4% at PEGV start to 53.7% at year 1, and reaching 75.4% at year 10 with the use of ≥30 mg PEGV/day in an increasing proportion of patients.
conclusionThis comprehensive review of the complete cohort in ACROSTUDY confirmed the overall favourable benefit-to-risk profile and high efficacy of PEGV as mono- and combination therapy in patients with an aggressive course/uncontrolled/active acromegaly requiring long-term medical therapy for control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.